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Rift Valley Fever Virus (RVFV) is a vector-borne infection endemic to the Horne of 
Africa; However, outbreaks in the Arabian Peninsula in 2001 demonstrate its expanding range. 
Humans can develop encephalitis as a result of RVFV infection. Our lab uses an 
immunocompetent Lewis rat model to study neuropathogenesis of RVFV. With this model, Lewis 
rats uniformly develop lethal encephalitis within 7 – 8 days after aerosol exposure. In contrast, 
Lewis rats infected subcutaneously do not develop apparent disease except at very high doses. The 
public health significance of RVFV is that it has the potential to natural spread throughout the 
world and it could be used as a potential bioweapon. The goal of this study is to characterize the 
phenotypes, timing, and extent of immune cell infiltrate into the CNS of RVFV-infected Lewis 
rats. Lewis rats were infected with RVFV ZH501 by aerosol or subcutaneous routes, and 
subsequently serially-sacrificed between 1 and 7 days post infection. Rat immune cells were 
isolated from brains via percoll gradients, stained with the appropriate antibodies, run on a BD 
LSRII flow cytometer, and analyzed with FlowJo 7.6.5.  
In aerosol-infected rats, the leukocyte infiltrate 5 days post infection and later consisted of 
primarily neutrophils, corresponding to the clinical window. Despite no apparent disease, rats 
infected subcutaneously had detectable infiltrate primarily consisting of phenotypic CD4+ T cells. 
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v 
These findings suggest that aerosol-infected rats mainly exhibit innate leukocyte infiltration to the 
brain while subcutaneous have limited leukocyte infiltration and display a stronger adaptive 
immune response. The relative contributions of viral cytopathology versus immunopathology 
remain to be determined, but this study represent the first attempt to characterize the leukocytic 
component of RVFV neurological disease.  
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1.0  INTRODUCTION 
1.1 VIRAL ENCEPHALITIS  
Encephalitis is the inflammation into the central nervous system (CNS) including the 
parenchyma as well as the meninges. The etiological agents of encephalitis are generally derived 
from either infectious agents or autoimmune disease. On a global scale, encephalitis is caused 
primarily by viral pathogens, such as Japanese Encephalitis Virus (JEV) and Herpes Simplex Virus 
(HSV) (1). These viruses pose a conundrum for the immune system, where it must respond to 
eliminate the viral insult while not causing irreparable damage to the neuronal network and 
function. In a healthy individual, the CNS is considered an immune privileged site with almost no 
immune activity beyond surveillance for potential damage by resident cells (2, 3). Safeguards 
against immune activation in the CNS include primary antigen presentation outside the CNS in the 
cervical lymph nodes (3), low levels/no MHC I expression on healthy neuronal cells (4), 
expression of FAS ligand by many CNS cells to prevent cytotoxic T cell activity (5), and the blood 
brain barrier (BBB) separation from circulation.  However, during viral encephalitis these healthy 
immune suppressive mechanisms are suspended by the detection of viral replication, leading to 
leukocyte infiltration to the CNS. The pathways of viral encephalitis are varied, based on viral 
tropism, host functions, and the route of entry to the CNS, and therefore are complicated to study 
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as a general phenomenon. Herein, viral entry and host barriers to the CNS are reviewed as well as 
host immune responses to viral insults within the CNS.  
1.1.1 Viral Blood-Brain Barrier interactions for entry to CNS 
Viral entry to the CNS is poorly understood for many viruses. The BBB is known to play 
an integral role in regulating entry to the CNS (2). The BBB is a multi-layered endothelial cell 
membrane that is joined together through tight-junctions, effectively separating circulation from 
the CNS vasculature. This membrane is maintained by various resident immune cells that prevent 
biological insults. Astrocytes play a disproportionate role in the maintenance and phenotype of the 
BBB through physical contact with the endothelial cells and secretion of cytokines (6). However, 
viruses have evolved several mechanisms by which to subvert this physical barrier and gain entry 
to the CNS, despite the many regulatory cells.  
The first two mechanisms utilize the BBB’s own selectivity to gain CNS entry.  One 
mechanism of this type is through direct attachment to BBB cellular markers, by the virus and 
facilitated entry in the endothelial cells, as seen with Epstein-Bar Virus (EBV) (7, 8). This 
mechanism is not without cost as the direct infection of the endothelial cells can induce an antiviral 
state, through production of type I interferons (IFN) and limit viral replication (8). Another 
mechanism is through infected leukocyte migration in to the CNS, also known as the “Trojan 
Horse (7).” Many lentiviruses utilize this method of entry to the CNS by infecting monocytes in 
the periphery, which replicate increasing peripheral viral loads (9). Eventually, the infected 
monocyte interacts with the BBB and undergoes transmigration. This successfully allows the virus 
to pass through the BBB without direct viral interaction with the endothelial layers. These two 
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methods utilize the BBB’s own markers to pass through, whether through direct interaction or an 
intermediary. 
The other two mechanisms avoid the BBB by using peripheral neurons to reach the CNS.  
The first of this type of mechanism is through the utilization of sensory neurons as seen with HSV 
(10). HSV infection initially takes place in epithelial cells and subsequently infects an innervating 
sensory neuron where it can eventually reach the CNS(10). Since sensory neurons are part of the 
peripheral nervous system (PNS), they are not protected by the BBB. Once in the sensory neuron 
the virus is retro-trafficked to the basal ganglia where it may enter the CNS through synaptic 
connections (10). The second mechanism of entry of this type is through motor neurons. While 
HSV can also enter through this mechanism other viruses exclusively use this mechanism, such as 
rabies virus. This utilizes the same means that HSV does in sensory neurons, but with motor 
neurons (7). These peripheral neurons are not without their own protective immune cells, which 
help pose an additional barrier to undetected viral entry to the neurons and CNS.  
Whichever entry mechanism is used by a virus, BBB integrity can be depleted and can 
cause breakdown. It has been demonstrated that matrix metalloproteinase-9 (MMP-9) is 
upregulated during acute brain injury and leads to BBB breakdown (11). MMP-9 is also known to 
be upregulated in JEV through simulation of the NFkB pathway astrocytes from viral presentation 
(12). BBB integrity can also be decreased due to direct viral replication and subsequent damage 
(8). Regardless of how the BBB integrity is decreased, leukocytes are able to enter the CNS from 
the periphery in response to viral replication, leading to viral encephalitis.   
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1.1.2 Host Response 
The response of the host to the viral insults widely varies between viruses for several 
reasons, including the viral lifecycle. DNA viruses have a nuclear phase and can often go latent in 
the CNS, which can have the byproduct of immune evasion for the virus. Alternatively, RNA 
viruses typically do not have a nuclear phase and are more likely to cause acute viral infection. For 
the purposes of this paper only RNA virus host responses will be discussed. 
 The host immune response must attempt to balance effective viral elimination and neuronal 
network damage once virus has entered the CNS. IFNs are important components of the innate 
factors produced by host cells in response to viral infections. It has previously been thought that 
type 1 IFNs (IFN-1) were responsible for viral responses; it is now known that this is not correct 
and that both type 1 and type 2 IFNs have important roles in viral responses (13). However, the 
parenchyma of the brain lacks typical peripheral cells that produce IFNs during active viral 
encephalitis (13). It was recently found that despite neuronal suppression of IκBα by gangliosides, 
neurons are able to produce IFNs during early infection in an NFκB-independent manner (13, 14). 
Neurons and glial cells are able to produce IFNs and induce an innate antiviral state, slowing viral 
replication so that an adaptive response may be mounted. Viruses often target IFNs/IFN-producing 
pathways to prevent hindrance to their replication, such as NSs protein in Bunyaviruses (15) or 
NS2A protein of the Flaviviruses (16).  
Glial cells are also important in the early response of the CNS to viral infection. Microglia 
and astrocytes are important immune functioning glial cells that initiate local responses and begin 
recruitment of peripheral leukocytes to the parenchyma of the brain through cytokine production. 
Microglia are the self-renewing resident macrophage population that serve as the sentinel 
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surveillance system of the CNS (17).  Microglia are also one of the only cells to express MHC II 
in the parenchyma of the brain and  are largely responsible for the limited antigen presentation that 
takes place within the CNS (2, 18).  For these reasons, microglia are imperative to the initial 
immune response in the CNS to viral infection and the ensuing neuroinflammation.  
Both neurons and glial cells, chiefly microglia, send neurotropic chemokines to the 
periphery. This causes the infiltration of T lymphocytes, B cells, monocytes, natural killer cells 
and granulocytes into the CNS. Many of these cells, such as antigenspecific T lymphocytes and 
monocytes, can transmigrate through an intact BBB (19).  Monocytes can enter the CNS through 
the BBB where they can replenish depleted microglia (20-22). Conversely, there have been reports 
that the monocyte population cannot be distinguished from the microglial populations by 
extracellular markers. The replenished microglia phenotype could be monocytes that have entered 
due to the breakdown of the BBB and are not actually replenishing the microglial population (23). 
Therefore, to distinguish between microglia and monocytes, one must normally obtain additional 
information beyond extracellular markers. Monocytes are often found in the brain early during 
infection but this is not always the case.  Under certain viral encephalitic conditions, neutrophils 
have been known to cross the BBB during early infection (24). During transmigration of the BBB, 
neutrophils decrease the BBB vascular integrity, likely through MMP-dependent mechanisms 
(24). Therefore, neutrophils during early infection tend to be more associated with reduced BBB 
integrity, and thus more immune infiltrate. B and T cells infiltrate once an adaptive response can 
be mounted and assist in viral clearance or suppression.  
Reduction in the integrity of the BBB presents a question for those who study viral 
encephalitis: does the pathogenesis come from viral lysis/budding and resulting destruction of 
tissue, from the immune response to the infection, or both? Semliki Forest Virus (SFV) represents 
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an example of neurological disease as a strict result of the immune response. In SFV mouse 
models, it was determined that the virus infiltrates the CNS and the mice uniformly develop 
neurological disease through demyelination of the neurons. However, upon the depletion of CD8+ 
cytotoxic cells from the mice, there was no brain pathology, despite viral replication (25). 
Conversely, some viruses can directly infect neurons where they can lead to apoptosis or necrosis, 
damaging neuronal networks. In order to understand the viral encephalitis and for the rational 
development of treatments as well as vaccines, this etiology of neurological disease should be 
known to insure efficacy. 
1.2 RIFT VALLEY FEVER VIRUS 
1.2.1 Epidemiology 
Rift Valley Fever Virus (RVFV) is an arbovirus and member of phlebovirdae, endemic to 
most of Africa and since 2001 portions of the Middle East (26). Primarily RVFV is carried and 
spread through the Aedes mosquitos, but has been demonstrated to be transmitted through several 
arthropod vectors, including flies and ticks (26). In endemic regions RVFV is maintained in 
enzootic cycles where mosquitos interact with wild ungulates and allow the virus to continue 
circulating in low levels (27, 28). During these enzootic cycles, desiccated mosquito eggs are cable 
of harboring virus for years, leading to infected progeny after egg activation (26, 29). In the 
epizootic cycle, eggs hatch during the rainy season and the resulting progeny expand infectivity 
beyond wild ungulates and into domesticated ruminants as well as humans (30).  
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Infection in domestic ruminants can result in what is known as ‘abortion storms,’ where 
many pregnant animals have spontaneous abortions, a unique clinical feature of RVFV (26). While 
initial infection of these animals begins with vector transmission, interaction with infected tissue 
can result in transmission and amplification of the epizootic cycle (31). During epizootic 
outbreaks, human transmission can come from directly handling infected tissue, or animal product 
such as unpasteurized milk (31). While most of the human cases are asymptomatic, outbreaks have 
shown symptoms including ocular, neurologic, and hemorrhagic manifestations (31). While these 
symptoms are relatively rare, the results from ocular, hemorrhagic, or neurologic disease can have 
a lifetime impact on the individual who succumbs to the illness. Furthermore, many of those who 
are most at risk, shepherds and farmers, can be put out of work due to the illness and be unable to 
carry on their livelihood. Miscarriages have  also recently been linked with human RVFV infection 
(32).  This new finding is troubling, as many of the epizootic outbreaks in humans have been on a 
moderate scale, rarely impacting more than a few hundred people. However, should RVFV 
outbreak occur on a more global scale, something in the scale of a Zika or West Nile Virus 
outbreak, the result could potentially wipe out a generation.  
1.2.2 Public Health Significance  
Recent expansion of RVFV into the Arabian Peninsula in 2001 has shown that the virus is 
capable of spreading into new regions, particularly given the warming climate (33). Today, the 
Americas, Europe, and most of Asia remain free of this virus. However, zika, dengue,, and West 
Nile viruses have all demonstrated that arboviruses are more than capable of spreading globally, 
where they can lead to dramatic disease and sequelae. RVFV is no different than these other 
arbovirus, and the threat, in the case of RVFV, should be taken more seriously due to the potential 
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for infection and subsequent devastation of livestock, along with humans. Due to the 
aforementioned ‘abortion storms’ caused in domesticated ruminants as well as miscarriages and 
variety of diseases in humans, the spread of RVFV to a naïve area, could severely deplete the food 
supply as well as strain medical capabilities.  The possibly of spread to naïve areas is more feasible 
than ever with globalized trade, travel and a warming global climate.  
In addition to natural spread of the virus, RVFV has been labeled as a potential bioweapon 
due to ease of infection from inhalation (34). This route of transmission has been demonstrated 
before in several laboratories. Whether released purposefully or accidentally, RVFV would be 
difficult to recognize in a naïve population, and would spread rapidly as RVFV is promiscuous in 
the number of vectors that can spread it. Therefore, RVFV represents a significant and ever 
increasing threat to the modern world and its economy.  
1.2.3 Virology  
RVFV is a tripartite negative single stranded RNA virus. The segments of the genome are 
straightforwardly known as long (L), medium (M), and short (S) segments. The virion enters the 
cell through the binding of viral glycoproteins Gn and Gc to heparan sulfate and induce 
endocytosis, though the exact mechanism remains unknown (35). In a pH-dependent manner, the 
virus membrane fuses with the endosome membrane and the virus is able to escape destruction 
and begin the replication cycle. The L segment codes for a RNA-dependent RNA polymerase for 
viral transcription. The L segment is also capable of cap snatching to propagate the translation of 
the viral genome by host machinery (36). The M segment responsible for nonstructural protein 
(NSm) and the two glycoproteins (Gn and Gc) that are found on the envelope of the complete viral 
particle. The S segment is ambisense and codes for the second nonstructural protein (NSs) in the 
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positive polarity and in the negative polarity, the N protein.  Viral assembly occurs in a localize 
area of the cell, and the virus utilizes the endomembrane system for a lipid bilayer to egress from 
the cell.  
NSs is a key player in the viral immune evasion. NSs has been shown to block IFNs, 
particularly IFNs-1 in in vitro as well as in vivo models in a NFkB and IRF-3 independent fashion, 
as these are still activated during infection (37). Without the NSs protein, the virus is attenuated 
due to a robust immune response through type I interferons (IFN).  However, in Protein Kinases 
RNA-activated (PKR) deficient cells, a virus deficient in NSs retained pathogenicity, indicating 
that RVFV specifically targets the dsRNA recognition molecule and ubiquinates it for degradation.  
In addition to targeting the host viral sensor, RVFV also suppresses IFN-beta transcripts directly. 
It does this by forming a NSs homodimer which can then polymerize into a filament and interaction 
with Sin3A Associated Protein 30 (SAP30) (38). The interaction between NSs filament and SAP30 
causes histone rearrangement of the IFN gene, effectively silencing any transcriptional expression 
(38). It is believed that silencing is also done through the degradation of the p62 component of the 
pre-initiator complex for host polymerase II (15, 39).  
NSm also is utilized by RVFV as an immune evasion protein. NSm is made from the M 
segment and the initial translation of the segment yields a polyprotein, which is cleaved by host 
proteases into NSm1 and NSm2. NSm1 protein has been demonstrated to function as a direct 
inhibitor of caspase 8 induced apoptosis through mitochondrial localization and modulation with 
reactive oxygen species (40). Additionally, NSm1 has been associated with inhibition of caspase 
9 and 3, though the mechanism for these remains unknown (40).  The NSm2 has a unique function 
from NSm1, but may act as a surrogate for NSm1 (41). However, when the NSm sequence is 
removed from of the virus, the virus is unable to replicate in monocytes, whereas a single mutation 
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in either allows for the infection of monocytes (41). While it is not yet understood why this 
mutation results in poor monocyte infection, it demonstrates that NSm plays a role in evasion and 
survival of the virus in the host.  
1.2.4 Animal Model 
Several models for RVFV have been developed for studying each of the disease states 
(febrile, ocular, hemorrhagic, and neurological).  For neurological disease, an immunocompetent 
Lewis rat model has been developed when it is exposed through aerosol (AERO). When 
immunocompetent Lewis rats are exposed to AERO RVFV the mortality is 100% after 8 days of 
infection with as low as 103 PFU (42). This model has also demonstrated that the site of viral 
replication is in the brain tissue, as confirmed by plaque assay and PCR (42, 43). Subcutaneous 
(SC) RVFV exposed immunocompetent Lewis rats do not succumb to death and do not exhibit 
any apparent neurological disease after infection with the same strain of virus (42, 44). This makes 
immunocompetent Lewis rats an ideal candidate for understanding neurological disease, as 
exposure route determines a reliably uniform clinical disease.  
In the early stages of infection, 0 to 4 days post infection (dpi) in this model, there is 
transient viral replication in the periphery and no overt disease symptoms (43). The clinical 
window for AERO infection begins at 5 dpi until death, usually on day 7 or 8. The clinical window 
is determined when the animal becomes symptomatic, such as hunching of the back or rolling. 
Within this clinical window, weight loss, fever, decreased activity, altered posture, and perforin 
staining around eye, nose and mouth can be observed (43). Virus can be detected  at low levels in 
the brain within 24 hours after infection. Virus titers increase exponentially, reaching 106-108 pfu/g 
during the clinical window (5-7 dpi) (43). Pathological changes in the brain, indicating 
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encephalitis, can be seen as early as 4 dpi. The pathology also showed apoptosis of neural 
structures, vasculitis, and morphological neutrophils and other infiltrating leukocytes (43). Also 
corresponding with the beginning of the clinical window were spikes in several cytokines 
including, MCP-1, RANTES, IL-18 and interferon gamma.  
In the periphery, there was viral replication detected in several organs, as early as 1 dpi 
with AERO exposure (43). Many of the cytokines seen in the brain were also seen in the peripheral 
response, but at earlier time points, chiefly 4 dpi.  RANTES was an exception, which had biphasic 
modulation at both 1 and 5 dpi (43). Complete blood counts (CBC) were performed and 
demonstrated a continuous increase in granulocytes and thrombocytopenia. However, 
lymphocytes differed, with a biphasic modulation in serum at 1 and 5 dpi.  
Together the viral load and corresponding immune response paint a picture of systemic 
infection and later infiltration of cells into the brain to match the onset of neurological symptoms. 
The importance of the cells infiltrating the CNS is currently a topic that is unknown, but imperative 
if the neurological disease of RVFV is to be understood. Without a thorough understanding of the 
neurologic disease, effective therapeutics, vaccines, and clinical indicators will be difficult to 
develop. Moreover, RVFV neurological disease will also be nearly impossible to determine from 
other encephalitic viruses. For these reasons, we seek to understand the differences in immune cell 
infiltration to the CNS during both SC and AERO infection, to compare leukocyte phenotypes that 
may elucidate the discrepancies seen in the overt diseases of both routes.   
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2.0  SPECIFIC AIMS  
2.1 PROJECT STATEMENT 
The neurological disease caused by Rift Valley Fever Virus (RVFV) is poorly understood 
in all models. Our lab uses an immunocompetent Lewis rat model study the neurological 
component of RVFV. Lewis rats develop uniformly lethal encephalitis within 7 days after AERO 
exposure to RVFV. Conversely, Lewis rats injected SC with RVFV do not develop disease. During 
viral encephalitis, it is not well understood if neurological disease and subsequent death, as in the 
AERO-infected Lewis rats, is a result of virus-triggered cell death or an adherent immune 
response. One of the steps towards understanding the etiological cause of disease in AERO-
infected rats is to compare the immune infiltrate of the central nervous system (CNS) to non-
neurological disease infection, the SC-infection route. Additionally, neurological disease may be 
symptomatic of a systemic response, leading to eventual immune infiltration of the CNS. For this 
reason, it is important to also phenotype the leukocytes that are present in the circulation of both 
AERO- and SC-infected rats.  
The goal of these studies is to determine the phenotype of resident and infiltrating immune 
cells into the CNS, through flow cytometry, in order to better understand the nuances between SC 
and AERO infection for future testing of therapeutics in RVFV. It is also important in our attempt 
to understand how the peripheral immune response may correlate with encephalitis. Our 
hypothesis is that AERO exposed immunocompetent rats will exhibit large amounts of leukocyte 
infiltration near 5dpi while SC exposed will exhibit little or no leukocyte infiltration through the 
duration of the study.  
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2.2 PROJECT SPECIFIC AIMS 
Specific Aim 1: To determine the phenotype, timing, and extent of immune cell infiltrate 
to the central nervous system (CNS) of Lewis rats infected with RVFV by either SC or AERO 
routes.  
A. Using flow cytometry, the infiltration of leukocytes to the CNS after either AERO or 
SC infection will be compared over time based on extracellular markers. 
B. Using flow cytometry to study specific microglial and neutrophil populations in the 
CNS through the course of infection and to include earlier and later time points of 
infections. 
 
Specific Aim 2: To compare phenotypes of peripheral immune cells and how they relate 
to the observed phenotypes in the CNS as a result of infection with RVFV by either SC or AERO 
routes.  
A. Changes in blood derived leukocyte populations after either AERO or SC infection 
will also be compared to better understand systemic response prior to CNS infiltration 
using flow cytometry methods 
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3.0  METHODS 
3.1  ANIMAL INFORMATION  
Female immunocompetent Lewis rats were used in all time courses. These rats were 
between 8 and 10 weeks old. All rat studies were conducted under IUCUC approval, using number 
14125012.  
3.2 VIRUS INFORMATION  
All infections of immunocompetent Lewis rats utilized Rift Valley Fever Virus (RVFV) 
ZH501. This strain was provided by Barry Miller and Stuart Nichol from Center for Disease 
Control, Atlanta, GA. This virus is considered a Select Agent and was handled according to the 
biosafety specifications listed within this section. Virus was propagated in VeroE6 cells utilizing 
standard cell culture methods.  
3.3 BIOSAFETY  
All studies were conducted in the Regional Biocontainment Laboratory (RBL) at the 
Center for Vaccine Research (CVR) within the University of Pittsburgh. This facility is registered 
with the CDC/USDA for work with RVFV. All infected tissue handling was done at biosafety 
level 3 (BSL-3) environment and proper personal protective equipment was utilized. Samples that 
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were taken out of BSL-3 conditions were inactivated overnight (at least 12 hours) using 4% 
paraformaldehyde (PFA). In the RBL all infected samples were handled under a class II biological 
safety cabinet. Any waste generated was autoclaved prior to removal and any surfaces that came 
into contact with infected samples were disinfected with Vesphene II.  
3.4 ANIMAL INFECTION  
3.4.1  Aerosol  
All aerosol infections were performed by Dr. Douglas Reed and his lab. Rats received an 
average inhaled dose of 3x104 plaque-forming units (PFU) of ZH501 RVFV through an Aeroneb 
nebulizer (Aerogen, Inc, Chicago, IL) controlled by the Biaera AeroMP exposure system (Biaera 
Technologies, Hagerstown, MD).  Rats were exposed to aerosols for 10 minutes in a whole-body 
chamber located inside a class III biosafety cabinet. Aerosol samples were collected during 
exposures in liquid media inside an all-glass impinger which was used to determine the delivered 
inhaled dose using a plaque assay.  
3.4.2 Subcutaneous 
All subcutaneous (SC) (under the skin) infections were performed by Aaron Walters. Lewis 
rats were exposed to Isoflurane (USP NDC 11695-0500-2) in a drop container to induce general 
anesthesia. Rats were then exposed to dose of 500uL of 1.00E+06 ZH501 RVFV by SC injection. 
All SC infections were done using the hind legs of rats.  
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3.5 STUDY DESIGN 
For each time course, female immunocompetent Lewis rats were randomized into 
uninfected control, SC ZH501 exposure, or AERO ZH501 exposure groups. Each ZH501 exposure 
type were randomly assigned into day of sacrifice groups. Rats were serial sacrificed between 0 
and 7 days’ post infection (DPI). For AERO, if exposed rats met euthanasia criteria prior to 
designated day of sacrifice, they were sacrificed on that day. For aim1a 2 SC-infected rats and 
4AERO-infect rats were sacrificed for each day. For aim1b 3 SC-infected rats and 3 AERO-
infected rats were sacrificed for each day.   
3.6 BRAIN CELL ISOLATION  
Following euthanasia, each Lewis rat was perfused and brain extracted for cell isolation.  
Brains were stored in Hanks Buffer Salt Solution without calcium or magnesium (HBSS w/o) 
(Sigma H9394) until processing could be performed. Whole brains were then divided into 
hemispheres, covered with 1mL of digestion buffer, consisting of 10mg/ml DNase I (Sigma 
10104159001), 20mg/ml of collagenase (Sigma C2674-500mg), and 6.75mL of HBSS w/o. The 
sample was then chopped using a scalpel and covered with an additional 6.5mL of digestion buffer.  
The sample was then incubated at 37C for 45 minutes, with repeated agitation, using a transfer 
pipette, every 15 minutes to generate a homogenous liquid.  Once the sample was a homogenous 
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liquid, it was filtered using a 40uM strainer. The remaining homogenate was then suspended in 
12mL of wash buffer, consisting of 150uL of DNase I and 30.5ml HBSS with 3% fetal bovine 
serum (FBS). The solution was then centrifuged at 500 x gravity for 8 minutes at room temperature. 
The supernatant was then removed and the pellet suspended in an additional 18mL of wash buffer 
and centrifuged at 500 x gravity for 8 minutes at room temperature. Supernatant was then removed 
and the remaining pellet suspended in an 80% Percoll (Sigma GE17-0891-01), suspended in HBSS 
solution. The suspended pellet is then layers with 38% and 21% Percoll and topped with HBSS 
with 3% FBS. The Percoll gradient separates cell types by density and leukocytes, during 
centrifugation at 480 x gravity for 35 minutes, move to the third interface, that between the 80% 
and 21%. The third interface was extracted and suspended in 30mL HBS w/o with 3% FBS and 
centrifuged for 8 minutes at 300 x gravity. The supernatant was removed and the pellet was washed 
with 10mL of HBS w/o with 3% FBS. The supernatant was again discarded and the remaining 
pellet suspended in 1 ml FACS buffer. Cells were then counted and placed on ice until it could be 




Figure 1. Brain leukocyte isolation gradient using a Percoll gradient.  
3.7 STAINING PANELS 
CD45 is a tyrosine phosphatase on leukocytes that was used as a pan-leukocyte marker for 
all panels. CD68 is a lipoprotein binding receptor and is used as a pan-macrophage marker and 
could be used to identify microglia. CD163 is a scavenger receptor on macrophages and used to 
identify peripheral/infiltrating macrophages. Iba-1 is an ionized calcium binding molecule that is 
present on microglia. RP-1 is a rat neutrophil antigen and was thus used to identify neutrophils. 
CD11b is an integrin protein that can be used to identify microglia when co-localized with CD68 
or neutrophils when co-localized to RP-1. CD3 is a generic T lymphocyte marker. CD8 and CD4 
were used to identify the subtypes of lymphocytes.  
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3.8 STAINING PROTOCOLS 
For study number R31, three separate panels were used to stain for all tissue samples 
collected. Each panel was used to determine distinct populations. 
 
 
Table 1. Staining Panel for R31 experiments (Aim 1a and b). 
Neutrophil Panel 
 
Lymphocyte Panel  
Marker Clone (Format) Company  Marker Clone (Format) Company 
CD45 OX-1 (V450) BD 
 
CD45 OX-1 (V450) BD 
His-48 His-48 (FITC) BD 
 
CD3 1FA (APC) BD  
RP-1 RP-1 (PE) BD 
 
CD4  OX-35 (PE) BD  
CD11b            WT.5 (APC) BD 
 
CD8  OX-8 (FITC) BD 
     
Macrophage Panel  
   
Marker Clone (Format) Company    
CD45 OX-1 (V450) BD 
   
CD11b  WT.5 (APC) BD 
   
CD163  His-36 (PE) BD 
   
CD68   ED1 (FITC) BIORAD 
   
 
For clarification, a second set of experiments was performed in order to ensure proper 
identification of microglia and neutrophils. Two additional markers were included, calprotectin, 
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as a confirmation of RP-1 expression on neutrophils, and Iba-1, to confirm microglia populations 
beyond CD68 and CD11b co-expression.  The panels were also rearranged to ensure that 
neutrophils were not expressing “monocyte/macrophage,” markers (CD68, Iba-1, CD163), and 
macrophages/monocytes were not expressing “neutrophil markers,” (RP-1, Calprotectin) 
 







CD45  OX-1 (Pe-Cy7) BD 
 
CD45 OX-1 (Pe-Cy7) BD 
RP-1 RP-1 (BV786) BD  
 
RP-1 RP-1 (BV786) BD  
CD11b WT.5 (V450) BD 
 
CD11b WT.5 (V450) BD 
CD163 His-36 (PE) BD 
 
CD163 His-36 (PE) BD 
Calprotectin S100A9(FITC)BIORAD 
 
CD68  ED1(FITC)BIORAD 
   Iba-1 EPR6136(2)(Alexa647)ABCAM 
 
3.8.1 Brain Cell staining  
Leukocytes suspended in FACS buffer were placed in a V-bottom 96-well plate and 
centrifuged for 500x gravity for 4 minutes at 4C. A blocking solution, 2uL of anti-CD32 and 18uL 
of FACS buffer per sample, was added to each sample and the samples incubated for 20 minutes 
on ice in the dark. Cells were then washed twice with 200uL FACS buffer and a 500x gravity for 
4-minute centrifugation and stained with antibodies for 30 minutes on ice in the dark. The stained 
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samples were then washed twice with 200uL FACS buffer and a 500x gravity for 4-minute 
centrifugation followed by the addition of 200uL of 4% PFA for overnight inactivation.  
3.8.2 Whole Blood lysis and staining 
Blood is taken from each Lewis rat prior to euthanasia from 0 through 7 days post infection. 
50uL of whole blood was taken from each animal and directly stained with the appropriate amount 
of antibody for 15 minutes. 450uL of FACS lysis buffer was used to lyse red blood cells for 30 
minutes. Samples were then washed with FACS buffer and centrifuged for five minutes at 
500xgravity, twice. The samples were then inactivated with 500ul of 4% PFA overnight.    
3.9 GATING STRATEGY 
All samples were run on a BD LSR II and analyzed using Flowjo 7.6.5. All samples initial 
gate was a vital brain gate used for viability of leukocytes based on side scatter and granularity. 
All samples were then further refined using a double inclusion using forwards scatter and side 
scatter to prevent any confounding events. CD45 was then used to identify leukocytes in all 
samples. Distinction was made to differentiate between high and medium expression of CD45. 
These two gates served the parent gate for all subsequent gates shown.  
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4.0  RESULTS 
4.1 SPECIFIC AIM 1 
4.1.1 Specific Aim 1A 
In order to determine the timing, phenotype, and extent of immune infiltration, a serial 
sacrifice experiment was performed after rats were exposed to RVFV ZH501 through either AERO 
or SC routes.  Three rats were euthanized daily from 3 to 6 days post infection (dpi), where 
peripheral blood and CNS infiltrate were analyzed using flow cytometry. 
 Samples were run on BD LSRII flow cytometer, and analyzed using Flowjo 7.6.5. Initial 
analysis of all of brain samples was done using a vital brain gate that is used to determine viable 
immune cells based on side scatter and granularity (Figure 2A) (45). These events were further 
gated based on side scatter area and height (Figure 2B). This was further gated to reveal CD45 
expression versus side scatter (Figure 2C). Previous studies have shown that intermediate CD45 
expression (indicated as CD45med in Figure 2C) within the brain can be used to crudely identify 
resting microglia (45). Similarly, CD45high expression can be used to identify infiltrating 




Figure 2. Flow cytometry gating strategy on vital brain and singlet inclusion in AERO RVFV infected Lewis 
rat brain.   
 
Sample gating strategy from 6 dpi in AERO infected Lewis rat. A) Vital brain gate based on forward and side scatter 
for viable brain cells. B) Singlet inclusion to avoid any events that could give false associations of markers based on 
complexity. C) CD45+ vs SSC-A to distinguish leukocytes from other cells and debris.  
 
The expression of CD45, regardless of medium or high, can be used to determine number of 
leukocytes within each tissue sample based on total cell counts using a hemocytometer. Significant 
increases in total isolated cells were observed with AERO-infected throughout the time course, 





Figure 3. Number of leukocyte density cells isolated from brain samples after RVFV infection. 
Hemocytometer was used to calculate these values. Data taken from aim 1b. For illustrative purposes is displayed in 
aim 1a. P < 0.05 *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
 
As expected, flow cytometry indicated that in the brain of uninfected Lewis rats, most 
CD45+ cells were resting microglia (Figure 4A). In AERO-infected rats on 6 dpi, there was a 
notable population of CD45hi cells not seen in uninfected rats (Figure 4C). Surprisingly, there was 
also a small increase in CD45hi cells in SC-infected rats on 6 dpi. In the brains of AERO-infected 
rats there was an increase into the proportion of activated microglia/infiltrating leukocytes and 
concurrent decline in resting microglia at the onset of the clinical window (5 dpi), suggesting that 
these changes coincide with the clinical manifestations (Figure 5). Conversely, in the brains of SC-
infected rats there was a decrease in resting microglia and no significant change in activated 
microglia/infiltrating leukocytes (Figure 5). This suggests resting microglia are decreasing in both 
AERO- and SC-infected rats, but only AERO-infected rats experience an increase in CD45high cells 
which could be either infiltrating leukocytes or activated microglia. It is curious that AERO-
infected rats which develop lethal encephalitis have increased numbers of CD45hi leukocytes in 
the brain, while SC-infected rats which survive without apparent disease do not have the same 
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increase of CD45hi leukocytes. This finding suggests AERO-infected rats have more immune 
infiltrate or activated microglia in the CNS than the SC-infected.  
 
 
Figure 4. Flow cytometry gating strategy for crude identification of microglia and leukocyte infiltrate in RVFV 
infected Lew rat brain. 
 
All data gated on vital brain gate and singlet inclusion as in Figure 2. CD45medium crudely represent microglia. CD45high 
represent activated microglia or infiltrating leukocytes. All data was based on CD45+ populations A) Uninfected 
Lewis rat (control (CTL) B) 6dpi SC-infected rat C) 6 dpi AERO-infected rat  
 
 
Figure 5. Number of leukocytes in RVFV-infected rats based on CD45 expression and infection route. 
P < 0.05 = *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** Legend indicates route of infection with RVFV.  
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Figure 6. Neutrophil gating strategy for RVFV infected Lewis rat brain.  
A) Represents two CD45 expression versus side scatter. Gated on CD45high B) CD45high His-48, and RP-1 expression. 
C) Histogram showing D11b expression on His-48+, RP-1+ gated cells indicating two distinct populations. D) 
Placement of the distinct CD11b populations based on SSC property and CD45 expression.  
 
Further gating of CD45high cells allowed identification of this population, which based on 
side scatter, could be lymphocytes, granulocytes or myeloid cells (Figure 6A). In rats, all 
granulocytes should express CD45 at high levels and should also express His-48, a rat pan-
granulocyte antigen. RP-1, a neutrophil antigen in rats, can be further used to define the 
granulocytes, in addition to CD11b, an integrin subunit. The majority of the CD45high population 
expressed both His-48 and RP-1 (Fig. 6B). When CD11b+ expression of His-48+ and RP-1+ 
positive cells was examined, there were two populations, CD11bmed and CD11bhigh (Figure 6C). 
Additional gating of each population reveal differences in side scatter, with CD11bmed events being 
roughly macrophage side scatterd, while CD11bhigh events being roughly neutrophil side scatterd 
(Figure 6D). This could not be definitively determined in this experiment because macrophage 
markers were used in a separate panel. However, based on CD45high, His-48+, RP-1+, and 
CD11bhigh expression, there was anan influx of neutrophils at 5 dpi corresponding with the clinical 
window seen in AERO-infected rats. In the SC-infected rats, this influx from the control was not 






Figure 7. Neutrophil population in CNS by percentage of CD45high.  
Data determined through flow cytometry for both SC and AERO infected rats. Gating strategy for this data shown in 
figure 6. His-48 and RP-1 co-expression can be used to phenotypically distinguish neutrophils. The co-expression of 
His-48, RP-1, and CD11b is a more rigorous way to identify true neturophils.  
 P < 0.05  *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
 
Because macrophages are an important target for RVFV infection (41), we attempted to 
differentiate between infiltrating macrophages and activated microglia, which would both fall 
within the CD45high gate. In theory, activated microglia should be CD45high, CD68+ (a lysosome 
activity marker), CD11b+, but should not express CD163 (a scavenger receptor expressed on 
peripheral macrophages) (Figure 8).  Conversely, infiltrating macrophages would be CD45high, 
CD68+ CD163+.  Using differential expression of CD163, there was no significant change in 
percetnages in activated microglia for either SC or AERO -infected rats compared to control 
counterparts (Figure 9B). While this finding was no statistically significant, it was suggestive of a 
trend. Infiltrating macrophages (CD45high, CD68+, CD163+) were increased on 3dpi for both 




Figure 8. Macrophage gating strategy for CD45 high leukocytes in RVFV infected Lewis rat brain.  
A) Represents two CD45 expression versus side scatter. Gated on CD45high. B) CD45high cells by CD163 and CD68. 
Two populations, CD68+, CD163-, and CD68+, CD163+ double positive. C) Gated on CD68+ CD163- population to 
show CD11b expression to identify microglia. D) To show the side scatter and CD45 expression of phenotypic 
activated microglia.   
 
 
Figure 9. CD45high macrophage/microglia population in CNS by percentage of CD45high.  
Data determined through flow cytometry for both SC and AERO infected rats. Infiltrating macrophages identified as 
CD45high, CD68+ and CD163+ double positive (gating shown in figure 8). Activated microglia identified as 
CD45high, CD68+, CD163-, and CD11b+ (gating shown in figure 8). P < 0.05 *, P < 0.01 **, P < 0.001 ***, P < 
0.0001 ****  
To identify resting microglia and potential replenishing monocytes, we examined the 
CD45med population (Figure 10). Phenotypically, resting microglia should express CD45med, 
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CD68+, CD11b+, and CD163-. This phenotype was significantly depleted in both infection routes 
as early as 3dpi and remained until the end of the study (Figure 11 B). Potential replenishing 
macrophages express CD163+ along with CD68+ and CD11b+. Only SC-infected rats showed a 
significant increase in the potential replenishing phenotype on 6dpi as a percentage of CD45med. 
There was an increase over the time course studied for both routes but this increase was not 
significant when compared to uninfected controls (p value?) (Figure11A).  
 
 
Figure 10. Macrophage/microglia gating strategy in CD45medium in RVFV infected Lewis rat brain. 
A) Represents two CD45 expression versus side scatter. Gated on CD45medium. B) CD45medium cells by CD163 and 
CD68. Two populations, CD68+, CD163-, and CD68+, CD163+ double positive. C) Gated on CD68+ CD163- 
population to show CD11b expression to identify resting microglia. D) To show the side scatter and CD45 expression 






Figure 11. CD45medium macrophage/microglia population in CNS by percentage of CD45medium. 
Data determined through flow cytometry for both SC and AERO infected rats. Gating strategy shown in Figure 10. 
A) Presumptive infiltrating macrophages identified as CD45high, CD68 and CD163 double positive. B) Potential 
resting microglia identified as CD45high, CD68+, CD163-. Resting microglia further refined by CD11b positivity. P 
< 0.05 *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
 
While the majority of CD45high cells appeared to be of either granulocyte or monocyte 
lineage (Figs. 8,10), we also looked at T lymphocytes. T cells were phenotyped as CD45high and 
CD3+ (Figure 12A-B). When looking at this population, it increased as a proportion of the CD45high 
gate for SC-infected rats starting on 6dpi and, significantly decreases in AERO-infected rats 
starting on 5dpi, also corresponding to clinical window (p < .05) (Figure 13A). Further 
phenotyping T lymphocytes, CD4+ cells express CD45high, CD3+, and CD8- (Figure 12C).  These 
cells increased as a proportion of the CD45high population at 6dpi in the brains of SC-infected rats 
and decreased as a proportion of CD45high population in the brain of AERO-infected rats on 5dpi, 
(Figure 13 B-C).  For CD8+ cells, phenotyped as CD45high, CD3+ and CD4-, there was a 
proportional decrease starting at 5dpi in the brains of AERO-infected rats. SC-infected rat brains 
showed a transient proportional dip in CD8+ phenotype events only on 4dpi. (Figure13 B-C). It is 
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therefore, CD4+ T cells that are responsible for the proportional increase in CD3+ expression in 
the brains of SC-infected rats, while AERO-infected rats appear to have a proportional decrease in 




Figure 12. T Lymphocyte gating strategy in CD45high in RVFV infected Lewis rat brain. 
A) Represents two CD45 expression versus side scatter. Gated on  CD4high. B) CD45high cells by side scatter and CD3. 
C) Gated on CD3+ for CD8+ and CD4+ populations.   
 
 
Figure 13. CD45high T Lymphocyte population in CNS by percentage of CD45high. 
Data determined through flow cytometry for both SC and AERO infected rats. Gating shown in Figure 12. A) 
Represents CD45high CD3+ cells. B) represents CD45high, CD3+, and CD8+ cells. C) Represents CD45high, CD3+, and 
CD4+.  P < 0.05 = *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
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Overall, it appears that neutrophils are relevant on 5dpi for AERO-infected rats, corresponding to 
the clinical window observed. Alternatively, SC-infected rats demonstrated a more intermediate 
response in innate immune cells, but appeared to have a T lymphocyte dominated response 
compared to the control as well as the AERO-infected animals. It is also possible, that some of the 
extracellular markers overlap across phenotypes and could cause our results to not add up to 100%.  
4.1.2 Specific Aim 1b 
In order to get a better scope of the immune cells infiltrating the brain, we next combined 
our previous panels to understand the phenotypes and their timing in the brain better (Table 2). 
Here we used new clones of antibodies and different conjugated fluorophores from the previous 
experiment. This study was used to clarify some of the confounding phenotypes observed in aim 
1.  The gating strategy shown in Figure 14 A-C was again used.  Using a manual hemocytometer  
we were able to calculate the number of cells in each gate. This allowed for the direct comparison 
between SC-infected and AERO-infected. Using this method for CD45high and CD45med 
demonstrated that there were more cells in general in the AERO-infected than the SC-infected, but 







 Figure 14. Flow cytometry gating strategy for vital brain and singlet inclusion RVFV infected Lewis rat brain.  
Sample gating strategy from 6 dpi in AERO infected Lewis rat. Renewed gating strategy for expanded experiment. 
A) Vital brain gate to identify viable brain cells. B) Singlet inclusion. C) CD45 expression broken down by medium 
and high expression.  
 
 
Figure 15. Flow cytometry gating strategy for vital brain and singlet inclusion RVFV infected Lewis rat brain.  
Sample gating strategy from 6 dpi in AERO infected Lewis rat. Renewed gating strategy for expanded experiment. 
A) Cell count comparison for CD45high in aim1b B) Cell count comparison for CD45medum.  
P < 0.05 = *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
 
For confirmation of activated microglia (using the previously described phenotype of 
CD45high, CD68+ and CD11b+), we looked at co-expression of a potential microglia-specific 
marker, Iba-1. We demonstrated that there are two levels of CD11b expression, high and 
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medium, (Figure 15 A-B), confirming previous results (Figure 6). As suggested by Fig. 6, many 
of the events expressing CD11b at high levels did not express Iba-1, indicating that they are 
likely not microglia and are indeed likely neutrophils as suggested below (Figure 1616 D). 
However, the CD11bmed population does express more Iba-1, again confirming these are likely 
myeloid cells (Figure 1616 C).  
 
 
Figure 16. Microglial identification gating strategy for CD45high leukocytes in RVFV infected Lewis rat brain. 
All data gated on Vital brain gate and Singlet inclusion. A) CD45 positive events broken down into medium and high 
expression. B) CD11b and CD68 on CD45high cells. Two populations gated, CD11bhigh and CD11bmedium. C) 
Expression of CD163 and Iba-1 on CD68+ CD11bmedium cells. D) CD163 and Iba-1 expression on CD68+ CD11bhigh 
cells    
 
Using a similar gating strategy to identify microglia, peripheral macrophages were 
evaluated within the CD45high gate for expression of CD163 and Iba-1. These were gated for 
CD11b+ and CD68+ but RP-1- (Figure 1717 A-D). For the CD45high CD163+ Iba-1+ populations, 
we saw depletion from control levels throughout the study for both infection routes (Figure 1818 
A). For CD45high CD163+ Iba-1- populations we saw mixed decreases and control levels 
throughout the time course for both infection routes (Figure 18 B). For all CD45med CD163+ we 





Figure 17. Microglial identification gating strategy for CD45high leukocytes in RVFV infected Lewis rat brain. 
A) CD45 positive events broken down into medium and high expression. B) Gated on CD45high or CD45medium. CD163 
and Iba-1 used to compare microglia and peripheral cells expressing Iba-1. C) Gated on either CD163+ Iba-1+ or 









Figure 18. Infiltrating macrophages population in brain as percentage of either CD45high or CD45medium. 
Data determined through flow cytometry for both SC and AERO infected rats. Gating shown in figure 16. A) CD163+, 
Iba-1+, CD11b+, CD68+, RP-1- events in the CD45high gate. B) CD163+, Iba-1-, CD11b+, CD68+, RP-1- events in 
the CD45high gate. C) CD163+, Iba-1+, CD11b+, CD68+, RP-1- events in the CD45medium gate. D) CD163+, Iba-1-, 
CD11b+, CD68+, RP-1- events in the CD45medium gate. P < 0.05 = *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
 
Iba-1 is thought to remain constitutively expressed on microglia, making it a relatively 
specific microglial phenotypic marker (46). For this reason, we looked at all brain CD45+ cells, 
both high and medium, and the expression of Iba-1 across infection routes at 5dpi because this 
correlates to AERO clinical symptoms, (Figure 1919 A-C).  Of the Iba-1+ cells, we then looked at 
their distribution among CD45 expression, and found that many of these positive cells are in the 
CD45med range, right at the height of infection (Figure 1919 D).  Additionally, we looked at Iba-
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1+ cells distribution across CD163+, peripheral macrophage marker, (Figure 1919 E). Here we 
found that in AERO-infected rats, there is a distinct CD163+, Iba-1+ phenotype that neither the SC-
infected nor the control exhibits. This could mean that microglia are being replenished from the 
periphery, as previous studies have shown (20, 21), or could be the presence of peripheral 
monocytes that are phenotypically indistinguishable from microglia (23). To understand the 
relative breakdown of microglia phenotype in both CD45 populations, we used the exclusion of 
CD163+ and RP-1+, and the inclusion of CD68+, Iba-1+, and CD11b+ (Figure 20 A-D). Overall, 
phenotypic microglia became depleted in both infection routes and both CD45 expressions (Figure 
21 A-B). Interestingly, CD45med phenotypic microglia experienced a transient drop and a return to 
control levels, while AERO-infected only experience the drop (Figure 21 B). Together these data 
suggest that reduction in microglia could play a role in the neuropathogenisis of AERO-infected 






Figure 19. Microglia extracellular expression in infected Lewis rat brain at 5 dpi.  
A) Uninfected Lewis rat gated on all CD45 positive events to show Iba-1 expression. B) SC Lewis rat gated on all 
CD45 positive events to show Iba-1 expression.  C) AERO-infected Lewis rat gated on all CD45 positive events to 
show Iba-1 expression. D) Gated on all CD45, Iba-1 positive events across infections to show CD45 expression. E) 








Figure 20. Activated and resting microglia phenotype gating strategy in RVFV infected Lewis rat brain. 
All data gated on Vital brain gate and Singlet inclusion. A) CD45 positive events broken down into medium and high 
expression. B) Gated on CD45high or Medium expression to show Iba-1+ population. C) Gated on Iba-1+ to show CD68+ 
CD11b+ D) Gated on CD68+ CD11b+ expression to show CD163+ and RP-1+ exclusion.    
 
 
Figure 21. Activated and resting microglia phenotype in brain as a percentage of either CD45high or CD45medium.  
Data determined through flow cytometry for both SC and AERO infected rats. Gating shown in figure 19. A) 
Activated microglia phenotype: CD45high, Iba-1+, CD68+, CD11b+, CD163- and RP-1-. B) resting microglia 
phenotype CD45medium, Iba-1+, CD68+, CD11b+, CD163- and RP-1-.  
P < 0.05 = *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
 
 To confirm previous finding that His-48+ RP-1+ CD11bhigh cells are neutrophils (Fig. 6), 
we analyzed the co-expressionlooked at coexpression of RP-1, CD68, and CD163 (Figure 2222 
A-D). Using this new strategy, the majority of the RP-1+, CD11bhigh events also expressed CD68+, 
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pan macrophage marker, but did not express CD163+ (Figure 2222 C-D). This finding suggests 
that CD68+ may not be exclusive to macrophages. This may make sense, as CD68 is a marker for 
lysosomal function and neutrophils can perform lysosomal function. Therefore, we incorporated 
CD68+ events into the gating strategy, but excluded CD163+ and Iba-1+ as exclusive macrophage 
markers (Figure 23 A-C). Overall, the new gating strategy did not change our previous findings, 
(Figure 7), and demonstrated that phenotypic neutrophils are a large proportion of events seen in 
AERO-infected, starting 5dpi, and not significant in SC-infection (Figure 24).  
  
 
Figure 22. Phenotyping neutrophils using new panel for conformation of previous gating strategy.    
A) CD45 positive events broken down into medium and high expression. B) Gated on CD45high expression to show 
CD11b expression and RP-1 expression. C) Gated on RP-1+ and CD11b+ population to show CD68 expression and 





Figure 23. Neutrophil identification gating strategy in RVFV infected rat brain.    
A) CD45 positive events broken down into medium and high expression. B) Gated  on CD45high expression to show 
CD11b expression and RP-1 expression. C) Gated on RP-1+ and CD11b+ population to show Iba-1- and CD163-.  
 
 
Figure 24. Neutrophil phenotype in brain as a percentage of CD45high.  
Data determined through flow cytometry for both SC and AERO infected rats. Gating shown in Figure 22. Phenotyped 
as RP-1+, CD11b+, CD68+, Iba-1-, CD163-. P < 0.05 = *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
 
Finally, we tried to confirmed neutrophil phenotype of CD11b +, RP-1 + with Calprotectin, 
a neutrophil marker, (Figure 2525 A-D). It is plausible that RP-1 may have some off target effects, 
causing it to bind macrophages. To control for this, we excluded CD163+ events in the gating 
strategy (Figure 24 D). However, this still did not reflect our findings in Fig. 7 and 24 (Figure 26). 
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Both infection routes seem to mirror each other with respect to increases and decreases of CD45high 
events. Since these were gated on RP-1 and CD11b, they are likely neutrophils but calprotectin 
could be identifying a subset of the neutrophils.   
 
 
Figure 25. Neutrophil identification gating strategy using Calprotectin as confirmation. 
All data gated on Vital brain gate, singlet inclusion and CD45high expression.  A) Gated on CD45high events to show 
RP-1 and CD11b expression. B) Gated on CD11b and RP-1 positive events to show calprotectin expression. C) 
Calprotectin isotype to confirm gating strategy gating shown in B. D) Gated on calprotectin positive to show CD45 
expression and side scatter distribution.  
 
 
Figure 26. Neutrophils over time based on calprotectin confirmation.    
P < 0.05 = *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
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4.2 SPECIFIC AIM 2 
4.2.1 Specific Aim 2A 
For all brain samples in Aim 1, we have matched blood samples that we used to understand 
changes in cell phenotypes in the periphery that could correlated with viral encephalitis. As with 
the brain, there was a general gating strategy performed to initially analyze all whole blood samples 
from each infection route (Figure 2727 A-C).  Since there were clearly defined side scatter 
populations, these was used as an initial gate for lymphocyte, macrophage/monocyte, and 
neutrophil populations (Figure 2727 D).  
 
 
Figure 27. Flow cytometry gating strategy for leukocytes in RVFV infected Lewis rat whole blood.  
These gates represent the base gates for all other strategies shown in this aim.  A) This is ungated events shown by 
side scatter and granularity. B) Singlet inclusion to exclude any confounding cells. C) CD45+ gate to identify 
leukocytes. D) Leukocytes gated based on side scatter to reveal granulocytes, monocytes, and lymphocytes based on 
descending side scatter, respectively.  
 
There was a clear indication of systemic response in the AERO-infected rats, while the SC-
infected rats demonstrated fewer CD45+ events (Figure 2828 A-C). Moreover, there was a 
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significant increase in cells of granulocytic side scatter on 3, 4, and 6 dpi for AERO-infected rats, 
while there was no increase for SC-infected animals (Figure 29 A), and this confirms our 
previously published data showing granulocytosis in the blood as measured by standard CBC (43). 
Monocytes (based on light scatter properties) were not observed to change statistically 
significantly in either infection route at any time that was studied (Figure 29 B). However, 
lymphocytes were significantly decreased in AERO-infected rats starting on 3dpi, while there was 
no difference from SC-infected rats compared to the control (Figure 29 C). This could be due to a 
proportional increase in AERO-infected, as granulocytes based on side scatter are increasing at the 
same time (Figure 29 A and C). 
 
Figure 28. Breakdown of leukocytes based on side scatter across various infection routes at 6dpi for RVFV 
infected rat whole blood.  
 








Figure 29. Blood leukocytes side scatter and CD45 expression as a percentage of CD45+ gate.  
Data determined through flow cytometry for both SC and AERO infected rats. Gating shown in Figure 22. A) 
Granulocytes based on side scatter and CD45 expression. B) Monocytes based on side scatter and CD45 expression. 
C) Lymphocytes based on side scatter and CD45 expression. P < 0.05 = *, P < 0.01 **, P < 0.001 ***, P < 0.0001 
**** 
 
 For the identification of peripheral neutrophils, the same markers were used as in the brain 
(Figure 30 A-C). Here, almost all events that were this side scatter were His-48+, Rp-1+, and 
CD11b+. There was no difference in neutrophils in SC-infected animals over time, but there was 
an increase within the AERO-infected rats on 3, 4 and 6dpi (Figure 31). The initial increase in 
phenotypic neutrophils in the blood may give rise to the neutrophils seen in the brain on 5dpi, 






Figure 30. Neutrophil gating strategy for RVFV infected rat whole blood.  
 
All base gating is shown in Figure 26. A) Shows CD45+ leukocytes distinguished by side scatter.  B) Gated on 
granulocyte side scatterd population to show expression of His-48 and RP-1. C) Gated on His-48+, RP-1+ positive 
events to show CD11b expression.  
 
 
Figure 31. Neutrophil phenotype expression in whole blood as percentage of CD45+ events 
Data determined through flow cytometry for both SC and AERO infected rats. Gating shown in Figure 29. Neutrophils 
in whole blood were phenotyped as RP-1+, His-48+, and CD11b+. P < 0.05  *, P < 0.01 **, P < 0.001 ***, P < 0.0001 
**** 
 
 Next we turned our attention to macrophages/monocytes. While there was no difference in 
the number of macrophages based light scatter properties and CD45 expression,, there was a 
difference in their expression of the phenotypic markers CD163 and CD68. These cells were 
classified as M2 (CD163+ CD68-), M1 (CD68+ CD163-), or as double positive (CD163+ and 
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CD68+) (Figure 3232 A-B). This classification was based on a similar study that demonstrated the 
phenotypes of these cells in tumors (47). M1 macrophages were seen in proportional increases in 
only AERO-infected 5dpi (Figure 33 A). This finding is particularly interesting because M1 
macrophages are classical macrophages, associated with inflammation (47). M2 macrophages, 
generally thought of as immune suppressive, decreased for AERO-infected when compared with 
control for each time point studied. The high levels of this cell type make sense for the control, as 
a suppressive phenotype should be expected for a non-disease/infected state. SC-infected rats also 
saw a significant decrease in M2, but later, starting on 5dpi (Figure 3333 C). The retention of high 
M2 cells could have implications for viral control in the periphery. Double positive macrophages 
were seen at higher than control levels for all days of AERO-infected but only for 3 and 4dpi for 
SC-infected, (Figure 33 B). Therefore, it can be inferred that while there is not a significant change 
in the number of overall macrophages, there are phenotypic differences occurring during the 
course of each infection that could have an impact on the inflammatory response to the viral insult.  
 
Figure 32. Blood monocyte gating strategy in RVFV infected rat whole blood. 
All base gating is shown in Figure 26 A) Shows CD45+ leukocytes distinguished by side scatter. B) CD68 and CD163 






Figure 33. Monocyte/Macrophage marker expression in whole blood as a percentage of CD45+.   
Data determined through flow cytometry for both SC and AERO infected rats. Gating shown in Figure 31. A) non-
M2 macrophages are those events that are CD68+ and CD163- B) Macrophages CD163+ and CD68+ C) M2  
macrophages are those that are CD163+ and CD68-. P < 0.05 *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
 
T lymphocytes were also phenotyped in whole blood, (Figure 3434 A-C). Overall, there 
was not much fluctuation with overall T cells as determined by CD3+ as a percentage of 
lymphocyte side scatterd events (Figure 3535 A). Both CD4+ cells and CD8+ cells also did not 
change significantly during the course of infection for either infection route as a percentage of 
lymphocyte side scatterd events (Figure 3535 B-C). While overall there was a decrease of 




Figure 34. T Lymphocyte gating strategy in RVFV infected rat whole blood. 
All base gating is shown in Figure 26 A) Shows CD45+ leukocytes distinguished by side scatter. B) CD3 expression 
on lymphocyte-gated cells. C) CD4+ and CD8+ expression on CD3+ lymphocytes.   
 
 
Figure 35. T lymphocyte marker expression in whole blood as a percentage of CD45+.  
Data determined through flow cytometry for both SC and AERO infected rats. Gating shown in Figure 33. A) T 
lymphocytes phenotyped by CD3+. B) CD8+ lymphocytes phenotyped by CD3+ and CD8+. C) CD4+ lymphocytes 
phenotyped by CD3+ and CD4+. P < 0.05 = *, P < 0.01 **, P < 0.001 ***, P < 0.0001 **** 
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5.0  DISCUSSION  
RVFV is an arbovirus that poses a safety threat from both natural or intentional spread 
(48). This virus has the capability to cause severe disease in humans and can potentially wipe out 
swaths of livestock in its wake. Moreover, outbreaks appear to be increasing in frequency and 
scope, with an outbreak ongoing every year, somewhere, for the last six years. Using 
immunocompetent Lewis rats, we were able to uniformly recapitulate the neurological disease 
through AERO exposure to RVFV (43). In doing so, we were able to study the leukocytes entering 
the CNS throughout the course of infection and compare the neurological disease created by lethal 
AERO exposure to the sub-lethal SC exposure route, which exhibit no apparent disease. Leukocyte 
infiltration to the CNS is consistent with other viruses that result in encephalitis, such as JEV and 
new world alphaviruses (49, 50). Additionally, human cases of RVFV-induced encephalitis have 
demonstrated increased leukocytes present in the cerebral spinal fluid and brain pathology, 
suggesting that infiltration may be a part of human clinical disease as well (51). 
We observed a significant increase inf leukocyte density isolated from brains of AERO-
infected rats, but not from brains of SC-infected rats. This is suggestive of immune cell infiltration 
to the CNS from the periphery of the AERO-infected rats, resulting in encephalitis.  Alternatively, 
this could be the result of subsets of leukocytes already present in the CNS proliferating. This is 
unlikely to be the case, as previous experiments in our lab show that the reduced integrity of the 
BBB correlated with increased leukocytes, which seems to point more towards peripheral 
infiltration than expansion of already present leukocytes, though both may be happening at some 
level. For the CD45high and CD45med cells in each experiment, we saw differences based on whether 
we looked at proportions of cells within a given gate or absolute numbers, though both reflected 
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the same trends. This highlights an important drawback of doing this analysis through flow 
cytometry as it can make direct comparisons difficult between infection routes that result in more 
cells in the brain. Overall, we were able to suggest that AERO-infected did have more phenotypic 
leukocytes, both proportionally and in terms of cell counts, while both infection routes had more 
microglia than the control, just in terms of cell counts.  
 We sought to identify what cells constitute the CD45high population. Using histology, 
previous studies showed the appearance of neutrophils in the brain of rats dying from RVF 
encephalitis (43). Using His-48 (pan-granulocyte marker), RP-1 (neutrophil marker), and CD11b 
(integrin subunit), we found neutrophils in the CNS of AERO but not SC-infected rats. The 
increase in neutrophils occurred at 5 dpi, which is the start of the clinical window seen in the 
AERO-infected rats. For further confirmation of the neutrophil population, we conducted a 
subsequent study with additional markers. We gated on CD11bhigh and RP-1+ within the CD45high 
gate. Gated on the double positive population, we gated on the macrophage markers CD68 and 
CD163. Almost all RP-1+ CD11b+ events were also CD68+, much to our surprise. However, it is 
now understood that neutrophils can express CD68, as it is an indicator of lysosome activity (52). 
This is not a case of indiscriminate uptake of antibody, as the cells were neither positive for CD163 
nor Iba-1, as demonstrated through gating. Therefore, the neutrophil phenotype appears to be RP-
1+, CD11b+, and CD68+. The results of this new gating, however, did not alter our previous 
findings of neutrophil infiltration as a percentage of the CD45high population. Therefore, CD45high, 
RP-1+, CD11b+ is sufficient for phenotyping infiltrating neutrophils into the CNS and can be 
confirmed through these two experiments. 
We also looked at the RP-1+ CD11b+ phenotype and co-expression with calprotectin. 
Calprotectin is typically found on neutrophils or weakly on macrophages, where it functions as a 
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heterodimer antibacterial/fungal protein through metal sequestration and can be released from its 
cytosolic form in the lumen of the gut (53). When the calprotectin+ population was investigated, 
it was determined that some, but not all CD11b+, RP-1+ cells also expressed calprotectin. This 
could be because calprotectin is not exclusive to neutrophils entering the CNS and can be 
expressed on monocytes (53). Additionally, it is possible that calprotectin is found on a subset of 
neutrophils in the gut and not infiltrating neutrophils in the brain. RP-1 is a marker that has been 
shown to identify both immature and mature neutrophils in blood (54). Calprotectin, alternatively, 
has been shown in human neonates to be present more present with immature neutrophils (55). 
This suggests that these calprotectin+ events in rats, may be representative of immature neutrophils. 
Few studies have looked at calprotectin in the context of viral encephalitic disease, and more 
investigation is required to understand exactly what cells are expressing calprotectin in the event 
of viral encephalitis. The overall implications of calprotectin in the neutrophil population remain 
unclear.  
While there is still insufficient evidence to ascertain if the pathologic neurological disease 
exhibited in AERO-infected rats is due to virus itself or immunological damage, the increase in 
neutrophils may suggest a potential etiology. Neutrophils are highly inflammatory cells, often 
producing damage in an attempt to limit viral spread without regard to tissue preservation(56). 
Neutrophils have also been implicated in the loss of BBB integrity after transmigration, through 
an MMP dependent pathway, and could be implicated in the dramatic increase in leukocytes 
(CD45high) observed after their influx as seen in Japanese Encephalitis Virus (24, 49). Our data is 
also supported by a previous finding from our lab that Gro/KC, a rat neutrophil-attracting 
chemokine homologous to human CXCL1, was found to be elevated at 4 dpi in the serum of 
AERO-infected rats (43). High levels of serum Gro/KC the day prior to the influx of neutrophils 
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in the CNS may imply the recruitment and proliferation in the periphery and gives reason why 
peripheral neutrophils may be entering the CNS. Additional chemokines, such as MCP-1 were also 
found to be significantly elevated in the serum, and may contribute to this proposed means of 
leukocyte entry to the CNS. Overall, the presence of neutrophils, combined with previous 
pathological data seem to suggest that the immune response contributes to the overt disease state 
in the AERO-infected rats. Further research is needed to understand the implications of these 
findings. Neutrophil depletion studies could look at the neutrophils role in death from neurological 
disease in AERO. Using genetically modified rats that expressed a reporter protein in neutrophils 
would also be useful, as this could help explain infiltration of the neutrophil phenotype to the brain. 
Additional studies should be done to understand the effector function of neutrophils in the brain, 
as it is no clear what they are doing. A first look at this might include translational analysis of 
neutrophils, to determine what genes they are making into proteins for effector function.   
Unlike the significant changes in neutrophils, macrophages did not appear to be a 
significant contributor to disease in AERO-infected rats.  The lack of a true microglia specific 
marker has hampered our efforts as well as the field for some time.  We used Iba-1, a potential 
microglia-specific marker to determine if microglia were upregulating CD45 upon activation, as 
suggested by our earlier gating strategy (57). Our new gating strategy (Aim 1b) determined that 
activated microglia were depleted, as we had previously shown. This makes sense, as CD45high is 
also the gate where phenotypic neutrophils will be and if they are contributing more to the 
population of AERO-infected and expressing CD68 then we would expect less activated microglia 
phenotype as a proportion of CD45high. This also furthers the suggestion that AERO-infection 
immune response is driven by neutrophils in the CNS, since they make up a large percentage of 
the CD45high events. Conversely, SC-infected may be protected by an increased or retained 
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activated microglial population. Overall, CD45high macrophage linage populations do not appear 
to fluctuate in response to RVFV AERO-infection in rats, likely because of neutrophil infiltration. 
Blood macrophages also did not change. SC-infected rats also do not exhibit a large uptick in these 
phenotypes, proposing some other cell type could be involved in the lack of apparent neurological 
disease.  
Phenotypic microglia, like the potentially infiltrating macrophages, microglia did not seem 
change dramatically to compared to control levels. In the two experiments we demonstrated that 
SC-infected rats have an early increase from control levels, while AERO-infected seemed to have 
late phenotypic microglia. This finding could implicate a rapid innate response to RVFV in the 
lack of neurological disease in SC-infected, as virus has been found in the CNS and surrounding 
tissue as early as 2dpi (58). Microglia are tightly regulated in terms of immune function, so if they 
are able to control the infection early, it may reduce later responses when viral loads cause a 
cytokine storm as seen in AERO-infected rats  (43).This is the case in some Flaviviruses that cause 
encephalitis, such as dengue. Dengue infection has shown to be slowed down by the early 
activation of microglia (59).  Taken together, the role of microglia in the neurological disease may 
be an important one and are the first responders to viral insult, but are not clearly tracked through 
infection. Microglia depleted from the CD45med phenotype do not appear to be upregulating CD45 
and entering the activated microglia phenotype. While it is only speculative, it may be that these 
microglia are becoming infected themselves and dying before ever becoming activated. 
Alternatively, they may be dying after brief functional activation. This would fit with our data, as 
microglia are not appearing elsewhere. Having said this, our study looks at the proportions of 
leukocytes in the brain and additional work is required before insight into the role of microglia in 
RVFV infection can be fully understood.  
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 Lymphocyte infiltration was also identified in previous studies which suggested it may be 
important in RFVF encephalitis (58). One such study used intranasal and SC-infection of a mouse 
model, where it was demonstrated that SC-infected mice mounted a stronger T cell response and 
died later during infection compared to the intranasal-infected mice (58). This also correlated with 
increased viral loads in the brain of intranasal-infected mice compared to the SC-infected mice, 
suggesting the T cell response may control viral replication in the brain (58). Here we found the 
proportion of CD3+ cells was significantly higher for SC-infected rats on 6dpi, while AERO-
infected rats had decreased CD3+ cells in the CNS compared to controls as early as 5dpi. A word 
of caution should be used here, as the drop observed is based on the percentage of total cells, not 
an actual count. The decrease could be due to increased neutrophils in AERO–-infected rats. 
Further analysis of T lymphocytes revealed that there were CD4+ T cell responses in the SC on 
day 6dpi while AERO was significantly lower on 6dpi. Additionally, SC has a transient decrease 
in proportion of CD8+ cells on 3dpi, but then recovers to near control levels during the clinical 
window. This mirrors what was previously seen in the periphery by CBC and presence of 
RANTES, a lymphocyte chemokine, where there is a biphasic peak showing lymphocytes 
decreasing on 3dpi (43). It is unclear what implications this could have on the course of infection. 
However, the large T cell response for the SC-infected might be expected, given the location of 
initial infection. By infection taking place through the skin, the virus encounters far more antigen 
presentation cells, such as dendritic cells, that are absent in the CNS, where AERO infection is 
thought to take root. Therefore, more naïve T cells can be activated, more effectively in the SC-
infected than the AERO-infected, controlling the viral replication and reducing the apparent 
pathogenesis. Taken together, this suggests a strong component of the SC response is mediated by 
T cells, specifically CD4, while T cell appears to be lacking in the AERO-infected rats.    
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 Altogether, these data suggest two important points for RVFV infection and the resulting 
neurological disease. The first important point is the infiltration of neutrophils in AERO-infected 
on 5dpi and later while there is no significant neutrophil infiltration of the brain in SC-infected. 
This infiltration is the starkest difference between these infection routes and is confirmed by 
histology, cytokines present in both serum and brain, the same phenotypic neutrophils increasing 
in the serum a day before infiltration, and BBB breakdown. Our lab has recently learned that the 
BBB breaks down during RVFV AERO-infection through an MMP-9 independent manner. As 
previously mentioned, neutrophils produced MMP-9 during transmigration in other viral 
encephalitis infections and reduce vascular integrity of the BBB. The subsequent reduction in 
vascular integrity of this barrier can then allow unchecked immune infiltrate into the CNS of the 
AERO-infected. Therefore, these data put together suggest a mechanism for BBB, why AERO-
infected may see larger amounts of immune infiltrate than SC-infected, and potentially, why 
neurological disease occurs in AERO- but not SC-infected. The neutrophil dominated disease has 
been seen in other arboviruses such as Japanese Encephalitis Virus and West Nile Virus (12, 60). 
Neutrophils remain understudied in terms of virology and specifically their role in viral induced 
encephalitis and, as demonstrated through our work, likely play an important part in the role of 
immune response to neurological disease.  
The second important point is that SC-infected rats show an increase in CD4+ T cells, while 
AERO-infected does not significantly differ from controls. The larger number of CD4+ T cells in 
the SC-infection make sense, since the infection initial takes place were a large number of dendritic 
cells are present and can stimulate naïve T cells. Alternatively, the AERO-infected rats may have 
to rely on microglia, a poor antigen presenter, for T cell activation and thus elicit a more innate 
response to control infection. Several studies have demonstrated T cell activation resulting in 
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leukocytes that lack effector function from chronic  infection or poor antigen presentation (61, 62). 
In mouse models of RVFV, this same mechanism of CD4+ T cells lacking effector function has 
been suggested for the cause of death in intranasal infection but not subcutaneous injection of 
RVFV (58, 63). Therefore, this finding builds on an existing field of research that suggests an 
important role for CD4+ cells for SC-infection but not for AERO-infection. Overall, AERO-
infection appears to be dominated by neutrophil infiltration into the brain while SC-infection is 
dominated by CD4 cells, despite viral antigen in both brains (Figure 36).   
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